{"type":"img","src":"https://cdn.quv.kr/dftb6ow8k%2Fup%2F5c32ea85dae40_1920.png","height":90}
  • COMPANY
  • R&D PIPELINE
  • CRO SERVICES
  • CAREER
  • NEWS
  • CONTACT US
  • {"google":["Noto Sans","Poppins"],"custom":["Nanum Square","Noto Sans KR","Nanum Barun Gothic"]}
    ×
    섹션 설정
    {"type":"img","src":"https://cdn.quv.kr/dftb6ow8k%2Fup%2F5c32ea85dae40_1920.png","height":50}
  • COMPANY
  • R&D PIPELINE
  • CRO SERVICES
  • CAREER
  • NEWS
  • CONTACT US
  • R&D Pipeline

    Development Stage

    RUDACURE

    RudaCure Co., Ltd. develops treatments for diseases with sensory based disorders and high unmet needs. Pipeline is divided into treatments via Rac1 inhibition and TRPV1 antagonism. Programs targeting Rac1 include treatments for Dry Eye, Corneal Ulcers, Atopic Dermatitis, Psoriasis, Melanoma and Wet-AMD. Programs targeting TRPV1 include treatments for chronic pain indications such as osteoarthritis pain and, chemotherapy induced peripheral neuropathy (CIPN) and CRPS.

    Development Stage

    RUDACURE

    Rudacure Co., Ltd. develops ophthalmic diseases such as dry eye syndrome, senile macular degeneration, and develops neurological and cancerous pain.
    We are focusing on developing painkillers, and five new drug pipelines are currently under development.

    {"google":["Noto Sans","Poppins"],"custom":["Nanum Square","Nanum Barun Gothic","Noto Sans KR"]}{"google":["Noto Sans","Poppins","Roboto","Oswald"],"custom":["Nanum Square","Nanum Barun Gothic","Noto Sans KR"]}
    {"google":[],"custom":["Noto Sans KR"]}